Ingeneron, Inc.
InGeneron is a clinical-stage biotechnology company dedicated to developing evidence-based, minimally invasive regenerative cell therapies for orthopedic conditions. With over 20 years of research, the company focuses on unlocking the healing potential of patients' own regenerative cells processed at the point of care for same-day treatment. Their innovative platform, Transpose Ultra®, isolates regenerative cells from adipose tissue using proprietary enzymatic technology, supporting treatments for rotator cuff tears, knee osteoarthritis, back pain, and other orthopedic indications. The company is conducting several FDA-approved clinical trials to validate its therapies and aims to become the first FDA-approved regenerative cell therapy provider for orthopedic applications.
Industries
Nr. of Employees
small (1-50)
Ingeneron, Inc.
Sonnenstraße 24-26, 80331 Munich, Germany
Patents
Products
Point-of-care adipose-derived cell processing platform
An integrated system composed of an automated processing unit, single-use closed-system disposables and a cGMP-manufactured enzymatic reagent for rapid isolation of regenerative cells from adipose tissue at the point of care for same-day autologous therapeutic application.
Point-of-care adipose-derived cell processing platform
An integrated system composed of an automated processing unit, single-use closed-system disposables and a cGMP-manufactured enzymatic reagent for rapid isolation of regenerative cells from adipose tissue at the point of care for same-day autologous therapeutic application.
Services
On-site clinical service model enabling mini-liposuction adipose harvest, bedside processing of autologous regenerative cells using an automated closed-system platform, and image-guided re-administration within a single outpatient visit for investigational treatment in orthopedic and wound-healing indications.
Design, conduct and support of FDA-regulated and investigator-initiated clinical trials (feasibility through pivotal), including randomized double-blind study design, comparator arm implementation, multicenter site partnerships, patient enrollment logistics, and extended follow-up data collection.
On-site clinical service model enabling mini-liposuction adipose harvest, bedside processing of autologous regenerative cells using an automated closed-system platform, and image-guided re-administration within a single outpatient visit for investigational treatment in orthopedic and wound-healing indications.
Design, conduct and support of FDA-regulated and investigator-initiated clinical trials (feasibility through pivotal), including randomized double-blind study design, comparator arm implementation, multicenter site partnerships, patient enrollment logistics, and extended follow-up data collection.
Expertise Areas
- Point-of-care autologous adipose-derived cell therapy development
- Design and operational execution of randomized, double-blind, multicenter pivotal clinical trials
- Clinical translational research and preclinical modeling
- Histological and immunohistochemical validation of tissue regeneration
Key Technologies
- Automated point-of-care cell processing units (heating, agitation, centrifugation)
- Closed-system disposable kits for tissue processing
- Enzymatic tissue digestion for regenerative cell liberation (cGMP-manufactured reagent, HPLC-tested)
- Mini-liposuction adipose harvest
News & Updates
A comprehensive immunohistochemical analysis of a tendon biopsy from a 66-year-old patient demonstrated regenerative healing of the tendon without scar formation, indicating the potential of autologous adipose-derived regenerative cells (UA-ADRCs) in tendon repair.
The company has enrolled the first patients in a multi-center, double-blinded trial evaluating autologous cell therapy for partial rotator cuff tears, with FDA approval to begin the study. The trial aims to demonstrate the effectiveness of regenerative cell therapy compared to corticosteroid injections.
A comprehensive immunohistochemical analysis of a tendon biopsy from a 66-year-old patient demonstrated regenerative healing of the tendon without scar formation, indicating the potential of autologous adipose-derived regenerative cells (UA-ADRCs) in tendon repair.
The company has enrolled the first patients in a multi-center, double-blinded trial evaluating autologous cell therapy for partial rotator cuff tears, with FDA approval to begin the study. The trial aims to demonstrate the effectiveness of regenerative cell therapy compared to corticosteroid injections.